Targeting the endocannabinoid system for the treatment of cancer - a practical view

Current Topics in Medicinal Chemistry

Volumn 10, Issue 8, 2010, Pages 814-827

  Fowler, Christopher J ^a   Gustafsson, Sofia B ^a   Chung, Sui Chu ^a   Persson, Emma ^a   Jacobsson, Stig O P ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

2 arachidonoylglycerol; Anandamide; Cancer; Cannabinoid; Fatty acid amide hydrolase; Glioma; Monoacylglycerol lipase; Prostate cancer

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID;

APOPTOSIS; ARTICLE; ASTROCYTOMA; BREAST CANCER; CANCER CELL; CANCER THERAPY; CANCER TISSUE; CELL VIABILITY; COLORECTAL CANCER; DRUG DEVELOPMENT; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; NEOPLASM; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT;

AMIDOHYDROLASES; ANTINEOPLASTIC AGENTS; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; MONOACYLGLYCEROL LIPASES; NEOPLASMS;

EID: 77954378342     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791164201     Document Type: Article

References (108)

1. Pacher P.; Bátkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev., 2006, 58, 389-462.
2. Food and Drug Administration safety information and adverse event reporting programe. Cesamet (nabilone) capsules for oral administration. Available from: http://www.fda.gov/Medwatch/SAFETY/2006/May_PIs/Cesamet_PI.pdf
3. Maida, V.; Ennis, M.; Irani, S.; Corbo, M.; Dolzhykov, M. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J. Support. Oncol., 2008, 6, 119-124.
4. Health Canada. Authorization with conditions of Sativex® (Tetranabinex® and Nabidiolex®). Available from: http://www.hcsc.gc.ca/dhp-mps/alt_formats/hpfbdgpsa/pdf/prodpharma/sativex_fs_fd_109461-eng.pdf.
5. Munson, A.E.; Harris, L.S.; Friedman, M.A.; Dewey, W.L.; Carchman, R.A. Antineoplastic activity of cannabinoids. J. Natl. Cancer Inst., 1975, 55, 597-602.
6. Sarfaraz, S.; Adhami, V.M.; Syed, D.N.; Afaq, F.; Mukhtar, H. Cannabinoids for cancer treatment: progress and promise. Cancer Res., 2008, 68, 339-342.
7. Pisanti, S.; Malfitano, A.M.; Grimaldi, C.; Santoro, A.; Gazzerro, P.; Laezza, C.; Bifulco, M. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract. Res. Clin. Endocrinol. Metab., 2009, 23, 117-131.
8. Flygare, J.; Sander, B. The endocannabinoid system in cancerpotential therapeutic target? Semin. Cancer Biol., 2008, 18, 176-189.
9. Velasco, G.; Carracedo, A.; Blázquez, C.; Lorente, M.; Aguado, T.; Haro, A.; Sánchez, C.; Galve-Roberh, I.; Guzmán, M. Cannabinoids and gliomas. Mol. Neurobiol., 2007, 36, 60-67.
10. 9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett., 1998, 436, 6-10.
11. Jacobsson, S.O.P.; Rongård, E.; Stridh, M.; Tiger, G.; Fowler, C.J. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem. Pharmacol., 2000, 60, 1807-1813.
12. Galve-Roperh, I.; Sánchez, C.; Cortés, M.L.; del Pulgar, T.G.; Izquierdo, M.; Guzmán, M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med., 2000, 6, 313-319.
13. Salazar, M.; Carracedo, A.; Salanueva, I.J.; Hernández-Tiedra, S.; Lorente, M.; Egia, A.; Vázquez, P.; Blázquez, C.; Torres, S.; García, S.; Nowak, J.; Fimia, G.M.; Piacentini, M.; Cecconi, F.; Pandolfi, P.P.; González-Feria, L.; Iovanna, J.L.; Guzmán, M.; Boya, P.; Velasco, G. Cannabinoid action induces autophagymediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest., 2009, 119, 1359-1372.
14. Blázquez, C.; Salazar, M.; Carracedo, A.; Lorente, M.; Egia, A.; González-Feria, L.; Haro, A.; Velasco, G.; Guzmán, M. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res., 2008, 68, 1945-1952.
15. 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer, 2006, 95, 197-203.
16. Sarfaraz, S.; Afaq, F.; Adhami, V.M.; Mukhtar, H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res., 2005, 65, 1635-1641.
17. Chung, S.C.; Hammarsten, P.; Josefsson, A.; Stattin, P.; Granfors, T.; Egevad, L.; Mancini, G.; Lutz, B.; Bergh, A.; Fowler, C.J. A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur. J. Cancer, 2009, 45, 174-182
18. Sánchez, C.; de Ceballos, M.L.; Gomez del Pulgar, T.; Rueda, D.; Corbacho, C.; Velasco, G.; Galve-Roperh, I.; Huffman, J.W.; Ramón y Cajal, S.; Guzmán, M. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res., 2001, 61, 5784-5789.
19. Ellert-Miklaszewska, A.; Grajkowska W; Gabrusiewicz K; Kaminska B; Konarska L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res., 2007, 1137, 161-169.
20. Calatozzolo, C.; Salmaggi, A.; Pollo, B.; Sciacca, F.L.; Lorenzetti, M.; Franzini, A.; Boiardi, A.; Broggi, G.; Marras, C. Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurol. Sci., 2007, 28, 304-310.
21. Held-Feindt, J.; Dörner, L.; Sahan, G.; Medhorn, H.M.; Mentlein R. Cannabinoid receptors in human astroglial tumors. J. Neurochem., 2006, 98, 886-893.
22. 9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res., 2006, 66, 6615-6621.
23. Michalski, C.W.; Oti, F.E.; Erkan, M.; Sauliunaite, D.; Bergmann, F.; Pacher, P.; Batkai, S.; Müller, M.W.; Giese, N.A.; Friess, H.; Kleeff, J. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int. J. Cancer, 2008, 122, 742-750.
24. Gustafsson, K.; Wang, X.; Severa, D.; Eriksson, M.; Kimby, E.; Merup, M.; Christensson, B.; Flygare, J.; Sander, B. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int. J. Cancer, 2008, 123, 1025-1033.
25. Xu, X.; Liu, Y.; Huang, S.; Liu, G.; Xie, C.; Zhou, J.; Fan, W.; Li, Q.; Wang, Q.; Zhong, D.; Miao, X. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet. Cytogenet, 2006, 171, 31-38.
26. Wang, D.; Wang, H.; Backlund, M.G.; Dey, S.K.; DuBois, R.N. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res., 2008, 68, 6468-6476.
27. Bedoya, F.; Rubio, J.C.; Morales-Gutierrez, C.; Abad-Barahona, A.; Lora Pablos, D.; Meneu, J.C.; Moreno-Gonzalez, E.; Enriquez de Salamanca, R.; Vegh, I. Single Nucleotide Change in the Cannabinoid Receptor-1 (CNR1) Gene in Colorectal Cancer Outcome. Oncology, 2009, 76, 435-441.
28. Blázquez, C.; Carracedo, A.; Barrado, L.; Real, P.J.; Fernández- Luna, J.L.; Velasco, G.; Malumbres, M.; Guzmán, M. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J., 2006, 20, 2633-2635.
29. Gleason, D.F.; Mellinger, G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 1974, 111, 58-64.
30. Czifra, G.; Varga, A.; Nyeste, K.; Marincsák, R.; Tóth, B.I.; Kovács, I.; Kovács, L.; Bíró, T. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J. Cancer Res. Clin. Oncol., 2009, 135, 507-514.
31. Feigenbaum, J.J.; Bergmann, F.; Richmond, S.A.; Mechoulam, R.; Nadler, V.; Kloog, Y.; Sokolovsky, M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. USA, 1989, 86, 9584-9587.
32. 9-tetrahydrocannabivarin. Br. J. Pharmacol., 2008, 153, 199-215.
33. McPartland, J.M.; Glass, M.; Pertwee, R.G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol., 2007, 152, 583-593.
34. Agurell, S.; Halldin, M.; Lindgren, J.-E.; Ohlsson, A.; Widman, M.; Gillespie, H.; Hollister, L. Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev., 1986, 38, 21-43.
35. Melck, D.; De Petrocellis, L.; Orlando, P.; Bisogno, T.; Laezza, C.; Bifulco, M.; Di Marzo, V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology, 2000, 141, 118-126.
36. Blázquez, C.; González-Feria, L.; Alvarez, L.; Haro, A.; Casanova, M.L.; Guzmán, M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res., 2004, 64, 5617-5623.
37. Nithipatikom, K.; Endsley, M.P.; Isbell, M.A.; Falck, J.R.; Iwamoto, Y.; Hillard, C.J.; Campbell, W.B. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res., 2004, 64, 8826-8830.
38. Ramer, R.; Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst., 2008, 100, 59-69.
39. Sarfaraz, S.; Afaq, F.; Adhami, V.M.; Mukhtar, H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res., 2005, 65, 1635-1641.
40. Flygare, J.; Gustafsson, K.; Kimby, E.; Christensson, B.; Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett., 2005, 579, 6885-6889.
41. Mimeault, M.; Pommery, N.; Wattez, N.; Bailly, C.; Hénichart, J.P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate, 2003, 56, 1-12.
42. Endsley, M.P.; Thill, R.; Choudhry, I.; Williams, C.L.; Kajdacsy- Balla, A.; Campbell, W.B.; Nithipatikom, K. Expression and function of fatty acid amide hydrolase in prostate cancer. Int. J. Cancer, 2008, 123, 1318-1326.
43. Ruiz-Llorente, L.; Ortega-Gutiérrez, S.; Viso, A.; Sánchez, M.G.; Sánchez, A.M.; Fernández, C.; Ramos, J.A.; Hillard, C.; Lasunción, M.A.; López-Rodríguez, M.L.; Díaz-Laviada, I. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. Br. J. Pharmacol., 2004, 141, 457-467.
44. Fowler, C.J.; Jonsson, K.-O.; Andersson, A.; Juntunen, J.; Järvinen, T.; Vandevoorde, S.; Lambert, D.M.; Jerman, J.C.; Smart, D. Inhibition of C6 glioma cell proliferation by anandamide, 1- arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem. Pharmacol., 2003, 66, 757-767.
45. De Petrocellis, L.; Melck, D.; Palmisano, A.; Bisogno, T.; Laezza, C.; Bifulco, M.; Di Marzo, V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA, 1998, 95, 8375-8380.
46. Grimaldi, C.; Pisanti, S.; Laezza, C.; Malfitano, A.M.; Santoro, A.; Vitale, M.; Caruso, M.G.; Notarnicola, M.; Iacuzzo, I.; Portella, G.; Di Marzo, V.; Bifulco, M. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res., 2006, 312, 363-373.
47. Widmer, M.; Haneman, C.O.; Zajicek, J. High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. J. Neurosci. Res., 2008, 86, 3212-3220.
48. Shoemaker, J.L.; Ruckle, M.B.; Mayeux, P.R.; Prather, P.L. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J. Pharmacol. Exp. Ther., 2005, 315, 828-838.
49. C.J. The pharmacology of the cannabinoid system - a question of efficacy and selectivity. Mol. Neurobiol., 2007, 36, 15-25.
50. Bode, A.M.; Cho, Y.-Y.; Zheng, D.; Zhu, F.; Ericson, M.E.; Ma, W.-Y.; Yao, K.; Dong, Z. Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. Cancer Res., 2009, 69, 905-913.
51. Zygmunt, P.M.; Petersson, J.; Andersson, D.A.; Chuang, H.; Sørgård, M.; Di Marzo, V.; Julius, D.; Högestätt, E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 1999, 400, 452-457.
52. Maccarrone, M.; Lorenzon, T.; Bari, M.; Melino, G.; Finazzi-Agro, A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem., 2000, 275, 31938-31945.
53. Contassot, E.; Tenan, M.; Schnüringer, V.; Pelte, M.-F.; Dietrich, P.-Y. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol. Oncol., 2004, 93, 182-188.
54. Contassot, E.; Wilmotte, R.; Tenan, M.; Belkouch, M.C.; Schnüriger, V.; de Tribolet, N.; Burkhardt, K.; Dietrich, P.Y. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J. Neuropathol. Exp. Neurol., 2004, 63, 956-963.
55. Song, J.H.; Harris, M.S.; Shin, S.H. Effects of fetal bovine serum on ferrous ion-induced oxidative stress in pheochromocytoma (PC12) cells. Neurochem. Res., 2001, 26, 407-413.
56. 9-Tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress. Neuroscience, 2005, 134, 567-574.
57. Campbell, V.A. Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacology, 2001, 40, 702-709.
58. Bentzen, P.J.; Lang, F. Effect of anandamide on erythrocyte survival. Cell. Physiol. Biochem., 2007, 20, 1033-1042.
59. 9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptorindependent mechanism. FEBS Lett., 1999, 458, 400-404.
60. Hinz, B.; Ramer, R.; Eichele, K.; Weinzierl, U.; Brune, K. Upregulation of cyclooxygenase-2 expression is ivolved in R(+)- methanandamide-induced apoptotic death of human neuroglioma cells. Mol. Pharmacol., 2004, 66, 1643-1651.
61. 2+ levels and proliferation in canine renal tubular cells. Basic Clin. Pharmacol. Toxicol., 2006, 98, 416-422.
62. Gustafsson, S.B.; Lindgren, T.; Jonsson, M.; Jacobsson, S.O.P. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother. Pharmacol., 2009, 63, 691-701.
63. De Lago, E.; Gustafsson, S.B.; Fernández-Ruiz, J.; Nilsson, J.; Jacobsson, S.O.P.; Fowler, C.J. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J. Neurochem., 2006, 99, 677-688.
64. Yarrow, J.C.; Perlman, Z.E.; Westwood, N.J.; Mitchison, T.J. A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol., 2004, 4, 21.
65. Fowler, C.J.; Chung, S.C.; Persson, E. Cannabinoid receptorindependent actions of HU210 upon the viability and mobility of PC3 prostate cancer cells. FASEB J. 2009, 23, 761.6 (meeting abstract).
66. Athanasiou, A.; Clarke, A.B.; Turner, A.E.; Kumaran, N.M.; Vakilpour, S.; Smith, P.A.; Bagiokou, D.; Bradshaw, T.D.; Westwell, A.D.; Fang, L.; Lobo, D.N.; Constantinescu, C.S.; Calabrese, V.; Loesch, A.; Alexander, S.P.; Clothier, R.H.; Kendall, D.A.; Bates, T.E. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem. Biophys. Res. Commun., 2007, 364, 131-137.
67. Gallily, R.; Even-Chena, T.; Katzavian, G.; Lehmann, D.; Dagan, A.; Mechoulam, R. γIrradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk. Lymphoma, 2003, 44, 1767-1773.
68. Massi, P.; Vaccani, A.; Ceruti, S.; Colombo, A.; Abbracchio, M.P.; Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J. Pharmacol. Exp. Ther., 2004, 308, 838-845.
69. Vaccani, A.; Massi, P.; Colombo, A.; Rubino, T.; Parolaro, D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br. J. Pharmacol., 2005, 144, 1032-1036.
70. Massi, P.; Vaccani, A.; Bianchessi, S.; Costa, B.; Macchi, P.; Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell. Mol. Life Sci., 2006, 63, 2057-2066.
71. McKallip, R.J.; Jia, W.; Schlomer, J.; Warren, J.W.; Nagarkatti, P.S.; Nagarkatti, M. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol. Pharmacol., 2006, 70, 897-908.
72. Ligresti, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther., 2006, 318, 1375-1387.
73. McAllister, S.D.; Christian, R.T.; Horowitz, M.P.; Garcia, A.; Desprez, P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol. Cancer Ther., 2007, 6, 2921-2927.
74. Lee, C.-Y.; Wey, S.-P.; Liao, M.-H.; Hsu, W.-L.; Wu, H.-Y.; Jan, T.-R. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int. Immunopharmacol., 2008, 8, 732-740.
75. Kogan, N.M.; Rabinowitz, R.; Levi, P.; Gibson, D.; Sandor, P.; Schlesinger, M.; Mechoulam, R. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J. Med. Chem., 2004, 47, 3800-3806.
76. Kogan, N.M.; Blázquez, C.; Alvarez, L.; Gallily, R.; Schlesinger, M.; Guzmán, M.; Mechoulam, R. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol. Pharmacol., 2006, 70, 51-59.
77. Kogan, N.M.; Schlesinger, M.; Priel, E.; Rabinowitz, R.; Berenshtein, E.; Chevion, M.; Mechoulam, R. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol. Cancer Ther., 2007, 6, 173-183.
78. Sánchez, M.G.; Sánchez, A.M.; Ruiz-Llorente, L.; Díaz-Laviada, I. Enhancement of androgen receptor expression induced by (R)- methanandamide in prostate LNCaP cells. FEBS Lett., 2003, 555, 561-566.
79. Hart, S.; Fischer, O.M.; Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor α-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res., 2004, 64, 1943-1950.
80. Sarnataro, D.; Pisanti, S.; Santoro, A.; Gazzerro, P.; Malfitano, A.M.; Laezza, C.; Bifulco, M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol. Pharmacol., 2006, 70, 1298-1306.
81. Santoro, A.; Pisanti, S.; Grimaldi, C.; Izzo, A.A.; Borrelli, F.; Proto, M.C.; Malfitano, A.M.; Gazzerro, P.; Laezza, C.; Bifulco, M. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int. J. Cancer, 2009, 125, 996-1003.
82. Lee, Y.M.; Uhm, K.O.; Lee, E.S.; Kwon, J.; Park, S.H.; Kim, H.S. AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)- ATF3 (activating transcription factor 3) pathway. Biochem. Biophys. Res. Commun., 2008, 370, 641-645.
83. Fogli, S.; Nieri, P.; Chicca, A.; Adinolfi, B.; Mariotti, V.; Iacopetti, P.; Breschi, M.C.; Pellegrini, S. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptorindependent mechanism. FEBS Lett., 2006, 580, 1733-1739.
84. Jacobsson, S.O.P.; Wallin, T.; Fowler, C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther., 2001, 299, 951-959.
85. Zheng, D.; Bode, A.M.; Zhao, Q.; Cho, Y.Y.; Zhu, F.; Ma, W.Y.; Dong, Z. The cannabinoid receptors are required for ultravioletinduced inflammation and skin cancer development. Cancer Res., 2008, 68, 3992-3998.
86. Duntsch, C.; Divi, M.K.; Jones, T.; Zhou, Q.; Krishnamurthy, M.; Boehm, P.; Wood, G.; Sills, A.; Moore, B.M. 2nd. Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. J. Neurooncol., 2006, 77, 143-152.
87. Sarfaraz, S.; Afaq, F.; Adhami, V.; Malik, A.; Siddiqui, I.; Mukhtar, H. Cannabinoid receptors agonist WIN-55,212-2 inhibits angiogenesis, metastasis and tumor growth of androgen-sensitive prostate cancer cell CWR22R1 xenograft in athymic nude mice [abstract]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. Abstract nr 2195. Available online at http://www.aacrmeetingabstracts.org/
88. Kogan, N.M.; Schlesinger, M.; Peters, M.; Marincheva, G.; Beeri, R.; Mechoulam, R. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study. J. Pharmacol. Exp. Ther., 2007, 322, 646-653.
89. 9-Tetrahydro-cannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene, 2008, 27, 339-346.
90. Carracedo, A.; Gironella, M.; Lorente, M.; Garcia, S.; Guzmán, M.; Velasco, G.; Iovanna, J.L. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res., 2006, 66, 6748-6755.
91. McKallip, R.J.; Lombard, C.; Fisher, M.; Martin, B.R.; Ryu, S.; Grant, S.; Nagarkatti, P.S.; Nagarkatti, M. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood, 2002, 100, 627-634.
92. Kerbel, R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther., 2003, 2 (Suppl 1), S134-S139.
93. Céspedes, M.V.; Casanova, I.; Parreño, M.; Mangues, R. Mouse models in oncogenesis and cancer therapy. Clin. Transl. Oncol., 2006, 8, 318-329.
94. Liu, W.M.; Scott, K.A.; Shamash, J.; Joel, S.; Powles, T.B. Enhancing the in vitro cytotoxic activity of Δ9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk. Lymphoma., 2008, 49, 1800-1809.
95. Miyato H; Kitayama J; Yamashita H; Souma D; Asakage M; Yamada J; Nagawa H. Pharmacological Synergism Between Cannabinoids and Paclitaxel in Gastric Cancer Cell Lines. J. Surg. Res., 2009,155(1),40-47.
96. Pan, H.; Mukhopadhyay, P.; Rajesh, M.; Patel, V.; Mukhopadhyay, B.; Gao, B.; Haskó, G.; Pacher, P. Cannabidiol attenuates cisplatininduced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther., 2009, 328, 708-714.
97. Holland, M.L.; Allen, J.D.; Arnold, J.C. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur. J. Pharmacol., 2008, 591, 128-131.
98. Wang, T.; Collet, J.-P.; Shapiro, S.; Ware, M.A. Adverse effects of medical cannabinoids: a systematic review. CMAJ, 2008, 178, 1669-1678.
99. Lorente, M.; Carracedo, A.; Torres, S.; Natali, F.; Egia, A.; Hernández-Tiedra, S.; Salazar, M.; Blázquez, C.; Guzmán, M.; Velasco, G. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia, 2009, 57, 1374-1385.
100. 9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol., 2005, 174, 3281-3289.
101. R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol., 2009, 156, 397-411.
102. Potenzieri, C.; Harding-Rose, C.; Simone, D.A. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res., 2008, 1215, 69-75.
103. Khasabova, I.A.; Khasabov, S.G.; Harding-Rose, C.; Coicou, L.G.; Seybold, B.A.; Lindberg, A.E.; Steevens, C.D.; Simone, D.A.; Seybold, V.S. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J. Neurosci., 2008, 28, 11141-11152.
104. Petersen, G.; Moesgaard, B.; Schmid, P.C.; Schmid, H.H.; Broholm, H.; Kosteljanetz, M.; Hansen, H.S. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J. Neurochem., 2005, 93, 299-309.
105. Nithipatikom, K.; Endsley, M.P.; Isbell, M.A.; Wheelock, C.E.; Hammock, B.D.; Campbell, W.B. A new class of inhibitors of 2- arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem. Biophys. Res. Commun., 2005, 332, 1028-1033.
106. A.A.; Aviello, G.; Petrosino, S.; Orlando, P.; Marsicano, G.; Lutz, B.; Borrelli, F.; Capasso, R.; Nigam, S.; Capasso, F.; Di Marzo, V.; Endocannabinoid Research Group. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J. Mol. Med., 2008, 86, 89-98.
107. Bifulco, M.; Laezza, C.; Valenti, M.; Ligresti, A.; Portella, G.; Di Marzo, V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J., 2004, 18, 1606-1608.
108. Kathuria, S.; Gaetani, S.; Fegley, D.; Valiño, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med., 2003, 9, 76-81.